CRA was retained by the petitioner in an IPR proceeding at the Patent Trial and Appeal Board (PTAB) to determine whether there was evidence of commercial success for certain pre-operative skin sterilization products. CRA’s team also conducted analyses demonstrating that the commercial performance of the product did not change following the issuance of the challenged patent. The PTAB found all challenged claims unpatentable and credited the testimony provided by Dr. Sean Sheridan.
Recent trends in Rule 702 decisions – 2024
In this CRA Insights, we update the Rule 702 decision trends in last year’s Insights with 2023 data.[1] We also provide descriptions of four specific...